These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 183960)

  • 21. [New therapeutic indications for a dopamine antagonist, Piribedyl].
    Schmitt H; Laubie M; Poignant JC; Krikorian A; Evrard Y; Freyria JL; Arnaud F
    Sem Hop; 1978 Mar; 54(5-8):325-34. PubMed ID: 211628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
    Thobois S; Lhommée E; Klinger H; Ardouin C; Schmitt E; Bichon A; Kistner A; Castrioto A; Xie J; Fraix V; Pelissier P; Chabardes S; Mertens P; Quesada JL; Bosson JL; Pollak P; Broussolle E; Krack P
    Brain; 2013 May; 136(Pt 5):1568-77. PubMed ID: 23543483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to L-DOPA in multiple system atrophy.
    Parati EA; Fetoni V; Geminiani GC; Soliveri P; Giovannini P; Testa D; Genitrini S; Caraceni T; Girotti F
    Clin Neuropharmacol; 1993 Apr; 16(2):139-44. PubMed ID: 8477409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delusional infestation induced by piribedil add-on in Parkinson's disease.
    Kölle M; Lepping P; Kassubek J; Schönfeldt-Lecuona C; Freudenmann RW
    Pharmacopsychiatry; 2010 Aug; 43(6):240-2. PubMed ID: 20614418
    [No Abstract]   [Full Text] [Related]  

  • 26. Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience.
    Evidente VG; Esteban RP; Domingo FM; Carbajal LO; Parazo MA
    Parkinsonism Relat Disord; 2003 Dec; 10(2):117-21. PubMed ID: 14644004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonidine and the anti-parkinsonian response to L-DOPA or piribedil.
    Shoulson I; Chase TN
    Neuropharmacology; 1976 Jan; 15(1):25-7. PubMed ID: 768802
    [No Abstract]   [Full Text] [Related]  

  • 28. Actions of dopaminergic agonists in parkinsonism.
    McDowell FH; Sweet R
    Adv Neurol; 1975; 9():367-71. PubMed ID: 1096573
    [No Abstract]   [Full Text] [Related]  

  • 29. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    Turle-Lorenzo N; Maurin B; Puma C; Chezaubernard C; Morain P; Baunez C; Nieoullon A; Amalric M
    J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experimental and clinical study on the dopaminergic receptor stimulating agents (author's transl)].
    Ohmoto T; Miyamoto T; Baba Y
    No To Shinkei; 1977 Jul; 29(7):?31-40. PubMed ID: 409419
    [No Abstract]   [Full Text] [Related]  

  • 32. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
    Kondo T
    Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393
    [No Abstract]   [Full Text] [Related]  

  • 33. DA agonists -- non-ergot derivatives: piribedil: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S90-2. PubMed ID: 12211147
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease.
    Montastruc JL; Ziegler M; Rascol O; Malbezin M
    Mov Disord; 1999 Mar; 14(2):336-41. PubMed ID: 10091630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
    Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
    Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):21-4. PubMed ID: 14681961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The use of piribedil in early and late stages of Parkinson's disease].
    Fedorova NV; Kulua TK; Gubanova ЕN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):96-98. PubMed ID: 26525631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piribedil: sleep attacks, also in patients without Parkinson's disease.
    Prescrire Int; 2013 Nov; 22(143):265. PubMed ID: 24427837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):83-90. PubMed ID: 28745677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.